NCT05638295 2026-04-16
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
11 trialsNCT05554341 2026-04-13
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554380 2026-04-13
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT06311214 2026-04-13
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07284589 2026-04-08
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT01697527 2025-11-24
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03872427 2025-11-14
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06956391 2025-06-04
Ultralow Dose PET Imaging of 18F-FDG Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT04023240 2024-08-12
68-Ga-FAPI PET Imaging in Malignancy
Stanford University
Phase 2 Withdrawn
NCT00375830 2023-12-12
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Stanford University
Phase 2 Completed
NCT00119314 2015-05-27
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Phase 2 Withdrawn